 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Mar 22, 2024
P1, N=30, Completed, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
- || tigulixostat (LC350189) / LG Chem
New P1 trial: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Feb 25, 2024
P1, N=30, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- || tigulixostat (LC350189) / LG Chem
Clinical, Journal: Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial. (Pubmed Central) - Feb 3, 2024
Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024 No abstract available
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Effect of Tigulixostat on the Pharmacokinetics of Theophylline (clinicaltrials.gov) - Jan 2, 2024
P1, N=24, Completed, Sponsor: LG Chem
- || Review, Journal: Pipeline Therapies for Gout. (Pubmed Central) - Dec 22, 2023
A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study...Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.
- |||||| tigulixostat (LC350189) / LG Chem
Enrollment open: EURELIA2: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (clinicaltrials.gov) - May 23, 2023
P3, N=2542, Recruiting, Sponsor: LG Chem
New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects. Not yet recruiting --> Recruiting
- |||| tigulixostat (LC350189) / LG Chem
Clinical: 📑ECA fase 2 muestra eficacia significativa de tigulixostat frente a placebo en reducción de uricemia en #gota 🎯Úrico <5 mg/dl a 12 semanas: -Placebo: 2.9% -TGX 50: 47.1% -TGX 100: 44.7% -TGX 200g: 62.2% #gout #uricacid #tigulixostat @geacser @KenSaag https://t.co/1uXyWbJzbk (Twitter) - Jan 22, 2023
- || tigulixostat (LC350189) / LG Chem
Clinical, Journal: Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial (CLUE). (Pubmed Central) - Jan 18, 2023
Not yet recruiting --> Recruiting Tigulixostat significantly lowered sUA levels compared to placebo at all doses used with an acceptable safety profile.
- |||||| tigulixostat (LC350189) / LG Chem
Enrollment open: EURELIA1: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (clinicaltrials.gov) - Jan 10, 2023
P3, N=350, Recruiting, Sponsor: LG Chem
Tigulixostat significantly lowered sUA levels compared to placebo at all doses used with an acceptable safety profile. Not yet recruiting --> Recruiting
- |||||||||| tigulixostat (LC350189) / LG Chem
New P3 trial: EURELIA1: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (clinicaltrials.gov) - Oct 19, 2022
P3, N=350, Not yet recruiting, Sponsor: LG Chem
- |||||||||| tigulixostat (LC350189) / LG Chem
New P3 trial: EURELIA2: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (clinicaltrials.gov) - Oct 19, 2022
P3, N=2542, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Trial completion: Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects (clinicaltrials.gov) - Jan 6, 2022
P1, N=37, Completed, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
Trial completion: Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults (clinicaltrials.gov) - Jan 6, 2022
P1, N=23, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects (clinicaltrials.gov) - Jul 18, 2021
P1, N=36, Not yet recruiting, Sponsor: LG Chem
- ||| tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jun 18, 2021
P2, N=156, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> May 2021
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults (clinicaltrials.gov) - May 12, 2021
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Enrollment closed: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Apr 27, 2021
P2, N=152, Active, not recruiting, Sponsor: LG Chem
Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> May 2021 Recruiting --> Active, not recruiting
- || tigulixostat (LC350189) / LG Chem
Trial completion date, Trial primary completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Sep 21, 2020
P2, N=152, Recruiting, Sponsor: LG Chem
Recruiting --> Active, not recruiting Trial completion date: May 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Apr 2021
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial primary completion date: Renal PK Study of LC350189 (clinicaltrials.gov) - Sep 19, 2020
P1, N=37, Completed, Sponsor: LG Chem
Trial completion date: May 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Apr 2021 Recruiting --> Completed | Trial primary completion date: May 2020 --> Sep 2020
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults (clinicaltrials.gov) - Jun 25, 2020
P1, N=24, Completed, Sponsor: LG Chem
Recruiting --> Completed | Trial primary completion date: May 2020 --> Sep 2020 Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020
- || tigulixostat (LC350189) / LG Chem
Trial completion: Mass Balance Study of [14C]LC350189 in Healthy Volunteers (clinicaltrials.gov) - Jun 25, 2020
P1, N=6, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020 Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. (clinicaltrials.gov) - Jun 25, 2020
P1, N=24, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Not yet recruiting --> Completed | Trial completion date: Feb 2020 --> Nov 2019
- | tigulixostat (LC350189) / LG Chem
Trial completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jan 22, 2020
P2, N=190, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Completed | Trial completion date: Feb 2020 --> Nov 2019 Trial completion date: Oct 2020 --> May 2021
- ||| tigulixostat (LC350189) / LG Chem
Enrollment open: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jan 13, 2020
P2, N=190, Recruiting, Sponsor: LG Chem
Trial completion date: Oct 2020 --> May 2021 Not yet recruiting --> Recruiting
- || tigulixostat (LC350189) / LG Chem
Enrollment open: Renal PK Study of LC350189 (clinicaltrials.gov) - Nov 27, 2019
P1, N=48, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || tigulixostat (LC350189) / LG Chem
New P1 trial: The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults (clinicaltrials.gov) - Nov 4, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- | tigulixostat (LC350189) / LG Chem
New P1 trial: Mass Balance Study of [14C]LC350189 in Healthy Volunteers (clinicaltrials.gov) - Aug 28, 2019
P1, N=6, Not yet recruiting, Sponsor: LG Chem
- | tigulixostat (LC350189) / LG Chem
New P1 trial: Renal PK Study of LC350189 (clinicaltrials.gov) - Aug 26, 2019
P1, N=48, Not yet recruiting, Sponsor: LG Chem
- ||||| tigulixostat (LC350189) / LG Chem
New P2 trial: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Apr 30, 2019
P2, N=228, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
New P1 trial: The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. (clinicaltrials.gov) - Apr 24, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Enrollment change: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting N=102 --> 129
- ||| tigulixostat (LC350189) / LG Chem
Trial completion: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
N=102 --> 129 Recruiting --> Completed